Does the media prefer MANE or GMAB?

In the previous week, Genmab A/S had 1 more articles in the media than Veradermics. MarketBeat recorded 6 mentions for Genmab A/S and 5 mentions for Veradermics. Genmab A/S's average media sentiment score of 1.03 beat Veradermics' score of 0.39 indicating that Genmab A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Genmab A/S 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MANE or ASND more profitable?

Ascendis Pharma A/S has a net margin of 57.87% compared to Veradermics' net margin of 0.00%. Company Net Margins Return on Equity Return on Assets Veradermics N/A N/A N/A Ascendis Pharma A/S 57.87% N/A -8.37%

Does the media refer more to MANE or ASND?

In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Veradermics. MarketBeat recorded 7 mentions for Ascendis Pharma A/S and 5 mentions for Veradermics. Ascendis Pharma A/S's average media sentiment score of 1.27 beat Veradermics' score of 0.39 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Ascendis Pharma A/S 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MANE or BBIO more profitable?

Veradermics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. Company Net Margins Return on Equity Return on Assets Veradermics N/A N/A N/A BridgeBio Pharma -124.42% N/A -65.81%

Does the media refer more to MANE or BBIO?

In the previous week, BridgeBio Pharma had 5 more articles in the media than Veradermics. MarketBeat recorded 10 mentions for BridgeBio Pharma and 5 mentions for Veradermics. BridgeBio Pharma's average media sentiment score of 1.50 beat Veradermics' score of 0.39 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Pharma 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor MANE or ELAN?

In the previous week, Elanco Animal Health had 4 more articles in the media than Veradermics. MarketBeat recorded 9 mentions for Elanco Animal Health and 5 mentions for Veradermics. Elanco Animal Health's average media sentiment score of 1.27 beat Veradermics' score of 0.39 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Elanco Animal Health 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MANE or AXSM?

In the previous week, Axsome Therapeutics had 8 more articles in the media than Veradermics. MarketBeat recorded 13 mentions for Axsome Therapeutics and 5 mentions for Veradermics. Axsome Therapeutics' average media sentiment score of 1.03 beat Veradermics' score of 0.39 indicating that Axsome Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Axsome Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Veradermics (MANE) Competitors

$109.82 -6.04 (-5.21%)

Closing price 07/24/2026 03:59 PM Eastern

Extended Trading

$114.00 +4.18 (+3.80%)

As of 07/24/2026 07:34 PM Eastern

Compare

MANE vs. GMAB, ASND, BBIO, ELAN, and AXSM

Should you buy Veradermics stock or one of its competitors? MarketBeat compares Veradermics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Veradermics include Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry.

How does Veradermics compare to Genmab A/S?

Veradermics (NYSE:MANE) and Genmab A/S (NASDAQ:GMAB) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

Veradermics presently has a consensus price target of $153.00, suggesting a potential upside of 39.32%. Genmab A/S has a consensus price target of $39.28, suggesting a potential upside of 36.05%. Given Veradermics' higher possible upside, equities analysts plainly believe Veradermics is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

In the previous week, Genmab A/S had 1 more articles in the media than Veradermics. MarketBeat recorded 6 mentions for Genmab A/S and 5 mentions for Veradermics. Genmab A/S's average media sentiment score of 1.03 beat Veradermics' score of 0.39 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S has a net margin of 21.05% compared to Veradermics' net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Genmab A/S	21.05%	15.34%	8.94%

7.1% of Genmab A/S shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Genmab A/S has higher revenue and earnings than Veradermics. Veradermics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	N/A	-$1.32	N/A
Genmab A/S	$3.90B	4.61	$963M	$1.32	21.87

Summary

Genmab A/S beats Veradermics on 13 of the 14 factors compared between the two stocks.

How does Veradermics compare to Ascendis Pharma A/S?

Veradermics (NYSE:MANE) and Ascendis Pharma A/S (NASDAQ:ASND) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

Ascendis Pharma A/S has a net margin of 57.87% compared to Veradermics' net margin of 0.00%.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Veradermics has higher earnings, but lower revenue than Ascendis Pharma A/S. Veradermics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	N/A	-$1.32	N/A
Ascendis Pharma A/S	$814.57M	19.44	-$258M	$8.67	29.28

Veradermics presently has a consensus price target of $153.00, indicating a potential upside of 39.32%. Ascendis Pharma A/S has a consensus price target of $296.72, indicating a potential upside of 16.88%. Given Veradermics' higher probable upside, equities research analysts clearly believe Veradermics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.05

In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Veradermics. MarketBeat recorded 7 mentions for Ascendis Pharma A/S and 5 mentions for Veradermics. Ascendis Pharma A/S's average media sentiment score of 1.27 beat Veradermics' score of 0.39 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ascendis Pharma A/S beats Veradermics on 9 of the 11 factors compared between the two stocks.

How does Veradermics compare to BridgeBio Pharma?

Veradermics (NYSE:MANE) and BridgeBio Pharma (NASDAQ:BBIO) are both pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Veradermics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
BridgeBio Pharma	-124.42%	N/A	-65.81%

Veradermics currently has a consensus price target of $153.00, suggesting a potential upside of 39.32%. BridgeBio Pharma has a consensus price target of $95.21, suggesting a potential upside of 13.32%. Given Veradermics' higher possible upside, analysts plainly believe Veradermics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, BridgeBio Pharma had 5 more articles in the media than Veradermics. MarketBeat recorded 10 mentions for BridgeBio Pharma and 5 mentions for Veradermics. BridgeBio Pharma's average media sentiment score of 1.50 beat Veradermics' score of 0.39 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
BridgeBio Pharma	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

99.8% of BridgeBio Pharma shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Veradermics has higher earnings, but lower revenue than BridgeBio Pharma. Veradermics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	N/A	-$1.32	N/A
BridgeBio Pharma	$579.96M	28.37	-$724.93M	-$3.74	N/A

Summary

BridgeBio Pharma beats Veradermics on 8 of the 12 factors compared between the two stocks.

How does Veradermics compare to Elanco Animal Health?

Veradermics (NYSE:MANE) and Elanco Animal Health (NYSE:ELAN) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

In the previous week, Elanco Animal Health had 4 more articles in the media than Veradermics. MarketBeat recorded 9 mentions for Elanco Animal Health and 5 mentions for Veradermics. Elanco Animal Health's average media sentiment score of 1.27 beat Veradermics' score of 0.39 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elanco Animal Health	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Veradermics has higher earnings, but lower revenue than Elanco Animal Health. Veradermics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	N/A	-$1.32	N/A
Elanco Animal Health	$4.89B	2.54	-$232M	-$0.50	N/A

Veradermics presently has a consensus target price of $153.00, suggesting a potential upside of 39.32%. Elanco Animal Health has a consensus target price of $28.73, suggesting a potential upside of 15.37%. Given Veradermics' higher possible upside, analysts plainly believe Veradermics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

97.5% of Elanco Animal Health shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Veradermics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Elanco Animal Health	-4.95%	7.42%	3.66%

Summary

Elanco Animal Health beats Veradermics on 12 of the 14 factors compared between the two stocks.

How does Veradermics compare to Axsome Therapeutics?

Veradermics (NYSE:MANE) and Axsome Therapeutics (NASDAQ:AXSM) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

In the previous week, Axsome Therapeutics had 8 more articles in the media than Veradermics. MarketBeat recorded 13 mentions for Axsome Therapeutics and 5 mentions for Veradermics. Axsome Therapeutics' average media sentiment score of 1.03 beat Veradermics' score of 0.39 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Axsome Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

81.5% of Axsome Therapeutics shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Veradermics has higher earnings, but lower revenue than Axsome Therapeutics. Veradermics is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	N/A	-$1.32	N/A
Axsome Therapeutics	$638.50M	19.42	-$183.17M	-$3.73	N/A

Veradermics presently has a consensus price target of $153.00, indicating a potential upside of 39.32%. Axsome Therapeutics has a consensus price target of $261.48, indicating a potential upside of 8.50%. Given Veradermics' higher possible upside, equities analysts plainly believe Veradermics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Axsome Therapeutics	2 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.91

Veradermics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Veradermics' return on equity of 0.00% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Summary

Axsome Therapeutics beats Veradermics on 9 of the 14 factors compared between the two stocks.

Get Veradermics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MANE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MANE vs. The Competition

Export

Metric	Veradermics	Pharmaceutical Preparations Industry	Manufacturing Sector	NYSE Exchange
Market Cap	$4.58B	$966.46M	$7.24B	$23.46B
Dividend Yield	N/A	4.84%	40.99%	4.20%
P/E Ratio	-83.20	1.53	23.62	30.72
Price / Sales	N/A	105.16	160.98	166.59
Price / Cash	N/A	20.06	165.01	31.69
Price / Book	N/A	8.48	12.77	4.73
Net Income	N/A	-$3.23M	$120.21M	$1.07B
7 Day Performance	-1.61%	-2.80%	-0.94%	-0.44%
1 Month Performance	-8.16%	-4.40%	-1.97%	0.73%
1 Year Performance	N/A	28.83%	9.83%	14.12%

Veradermics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MANE Veradermics	2.7267 of 5 stars	$109.82 -5.2%	$153.00 +39.3%	N/A	$4.58B	N/A	N/A	19
GMAB Genmab A/S	4.7923 of 5 stars	$28.97 -0.4%	$38.21 +31.9%	+22.2%	$18.07B	$3.90B	21.95	3,029	Analyst Upgrade
ASND Ascendis Pharma A/S	4.7302 of 5 stars	$264.02 -1.7%	$295.67 +12.0%	+50.8%	$16.46B	$814.57M	30.43	1,189	News Coverage Positive News Analyst Forecast
BBIO BridgeBio Pharma	2.9786 of 5 stars	$82.28 -0.5%	$94.63 +15.0%	+84.0%	$16.07B	$579.96M	N/A	400	Positive News
ELAN Elanco Animal Health	3.7809 of 5 stars	$25.96 +1.6%	$28.55 +10.0%	+69.5%	$12.98B	$4.89B	N/A	9,400	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:MANE) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veradermics (MANE) Competitors

MANE vs. GMAB, ASND, BBIO, ELAN, and AXSM

How does Veradermics compare to Genmab A/S?

Summary

How does Veradermics compare to Ascendis Pharma A/S?

Summary

How does Veradermics compare to BridgeBio Pharma?

Summary

How does Veradermics compare to Elanco Animal Health?

Summary

How does Veradermics compare to Axsome Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MANE vs. The Competition

Veradermics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Veradermics (MANE) Competitors

MANE vs. GMAB, ASND, BBIO, ELAN, and AXSM

How does Veradermics compare to Genmab A/S?

Do analysts recommend MANE or GMAB?

Does the media prefer MANE or GMAB?

Is MANE or GMAB more profitable?

Do institutionals & insiders have more ownership in MANE or GMAB?

Which has higher earnings and valuation, MANE or GMAB?

Summary

How does Veradermics compare to Ascendis Pharma A/S?

Is MANE or ASND more profitable?

Which has higher valuation and earnings, MANE or ASND?

Do analysts rate MANE or ASND?

Does the media refer more to MANE or ASND?

Summary

How does Veradermics compare to BridgeBio Pharma?

Is MANE or BBIO more profitable?

Do analysts prefer MANE or BBIO?

Does the media refer more to MANE or BBIO?

Do insiders & institutionals have more ownership in MANE or BBIO?

Which has better valuation & earnings, MANE or BBIO?

Summary

How does Veradermics compare to Elanco Animal Health?

Does the media favor MANE or ELAN?

Which has better earnings & valuation, MANE or ELAN?

Do analysts rate MANE or ELAN?

Do insiders and institutionals have more ownership in MANE or ELAN?

Is MANE or ELAN more profitable?

Summary

How does Veradermics compare to Axsome Therapeutics?

Does the media favor MANE or AXSM?

Do insiders & institutionals believe in MANE or AXSM?

Which has preferable earnings & valuation, MANE or AXSM?

Do analysts recommend MANE or AXSM?

Is MANE or AXSM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MANE vs. The Competition

Veradermics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools